Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorLABADIE, Magali
dc.contributor.authorNARDON, Audrey
dc.contributor.authorCASTAING, Nadege
dc.contributor.authorBRAGANCA, Coralie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDAVELUY, Amelie
dc.contributor.authorGAULIER, Jean-Michel
dc.contributor.authorEL BALKHI, Souleiman
dc.contributor.authorGRENOUILLET, Marike
dc.contributor.authorFRENCH POISON CENTRE RESEARCH, Group
dc.contributor.authorTOURNOUD, Christine
dc.date.accessioned2024-05-06T11:32:08Z
dc.date.available2024-05-06T11:32:08Z
dc.date.issued2024-02-01
dc.identifier.issn1556-9519en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/199657
dc.description.abstractEnINTRODUCTION: Hexahydrocannabinol is a hexahydro derivative of cannabinol. Poisoning with hexahydrocannabinol was first observed in Europe in May 2022. METHOD: This is a retrospective observational study of cases of self-reported hexahydrocannabinol exposure reported to French poison centres between 1 January 2022 and 31 May 2023. RESULTS: There were 37 cases, including 19 in May 2023. The median age of the patients was 36 (interquartile range 28-43) years, and most were men. Eight patients had a history of substance use disorder. The route of exposure was ingestion in 24, inhalation (smoking or vaping) in 10, inhalation and ingestion in two and sublingual in one. Clinical features were neurological (85 per cent), cardiovascular (61 per cent), gastrointestinal (33 per cent), psychiatric (27 per cent) and ocular (21 per cent). Fifty-nine per cent of the patients were hospitalized. In four patients, the Poisoning Severity Score was 0 (asymptomatic); in 15 patients, the Score was 1 (minor); in 16, the Score was 2 (moderate); and in two cases, the Score was 3 (severe). In 70 per cent of patients, the outcome was known, and all recovered. Testing of biological samples was only undertaken in six cases. Five patients had positive blood or urine tests for hexahydrocannabinol; in two patients, tetrahydrocannabinol and metabolites were also detected. In addition, there was an additional patient in whom Δ(8)- and Δ(9)-tetrahydrocannabinol was detected in the substances used. DISCUSSION: Clinical effects reported in this series included neuropsychiatric and somatic effects. Whilst these cases related to self-reported hexahydrocannabinol use, it is likely that tetrahydrocannabinol use also contributed to the effects in a substantial proportion of cases. This study has some limitations, such as the lack of available information due to the retrospective nature of the study. As a result, it probably overestimates the number of moderate and severe cases due to under-reporting of cases of little or no severity. Analysis of the patient's blood and urine was performed only in six patients, so we cannot be certain that the products consumed by the other patients were hexahydrocannabinol. CONCLUSION: The clinical effects attributed to hexahydrocannabinol were neurological, cardiovascular, gastrointestinal, psychiatric and ocular predominantly and were sometimes serious.
dc.language.isoENen_US
dc.subject.enHexahydrocannabinol
dc.subject.enCannabinoid
dc.subject.enNew psychoactive substances
dc.subject.enPoison centre
dc.subject.enPoisoning
dc.title.enHexahydrocannabinol poisoning reported to French poison centres
dc.title.alternativeClin Toxicol (Phila)en_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/15563650.2024.2318409en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38426845en_US
bordeaux.journalClinical Toxicologyen_US
bordeaux.page112-119en_US
bordeaux.volume62en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04569510
hal.version1
hal.date.transferred2024-05-06T11:32:10Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Toxicology&rft.date=2024-02-01&rft.volume=62&rft.issue=2&rft.spage=112-119&rft.epage=112-119&rft.eissn=1556-9519&rft.issn=1556-9519&rft.au=LABADIE,%20Magali&NARDON,%20Audrey&CASTAING,%20Nadege&BRAGANCA,%20Coralie&DAVELUY,%20Amelie&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée